CTOs on the Move

WithMe Health

www.withmehealth.com

 
WithMe Health replaces an employer`s pharmacy benefit manager (PBM) with a personalized medication guidance solution that greatly improves on and expands the scope of services available in the market today. Our modern technology and rich datasets allow consistent application of proven science to create individualized medication experiences for employees and their families that are proactive, adaptive, convenient and engaging. With an innovative, outcomes-oriented business model that aligns interests across the pharmaceutical value chain, WithMe Health optimizes health outcomes and value while substantially reducing costs for employers.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

WithMe Health raised $20M on 11/24/2020

Similar Companies

G3 Medical

G3 Medical is a Asheville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mercy Health System

Mercy Health System is the largest Catholic healthcare system serving the Delaware Valley and is a member of Catholic Health East, a multi-institutional, Catholic health system co-sponsored by 13 religious congregations and Hope Ministries.

Ganim Medical

Ganim Medical is a Delaware, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bay Area Medical Center

Bay Area Medical Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Marinette, WI. To find more information about Bay Area Medical Center, please visit www.bamc.org

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.